blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2599475

EP2599475 - Pharmaceutical composition having desirable bioavailability [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  24.03.2017
Database last updated on 20.05.2024
FormerGrant of patent is intended
Status updated on  14.03.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): DK		published on 29.05.2024 [2024/22]
Applicant(s)For all designated states
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
[2017/17]
Former [2013/23]For all designated states
Alcon Research, Ltd.
6201 South Freeway, Mail Code TB4-8
Fort Worth, TX 76134-2099 / US
Inventor(s)01 / Kabra, Bhagwati P.
2205 Eagles Nest Drive
Euless, TX Texas 76039 / US
02 / Carreras, Nuria
Ametller 9
08140 Caldes De Montbui (Barcelona) / ES
03 / Cuchi, Mónica
Cl. peru 58-60, 2°, 1a
Barcelona / ES
04 / Galán, Francisco Javier
C/ Dels Pins 19
08329 Teia (Barcelona) / ES
05 / Mridvika
Cl. Burriac, 40
08348 Cabrils (Barcelona) / ES
06 / Puig, Elena González
Consell De Cent 432, 6° 3
08013 Barcelona / ES
07 / Jiménez, Nuria
Espronceda 36, Ppal. 1
08005 Barcelona / ES
08 / Martínez, Carmen
Avinguda Can Vilardebó, 20
08185 Llicà De Vall (Barcelona) / ES
 [2013/23]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[N/P]
Former [2017/17]Kingsbury, Oliver William
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2013/23]Teipel, Stephan, et al
Lederer & Keller Patentanwälte Unsöldstrasse 2
80538 München / DE
Application number, filing date12193597.713.03.2009
[2013/23]
Priority number, dateUS20080037117P17.03.2008         Original published format: US 37117 P
US20080111920P06.11.2008         Original published format: US 111920 P
[2013/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2599475
Date:05.06.2013
Language:EN
[2013/23]
Type: A3 Search report 
No.:EP2599475
Date:21.08.2013
Language:EN
[2013/34]
Type: B1 Patent specification 
No.:EP2599475
Date:26.04.2017
Language:EN
[2017/17]
Search report(s)(Supplementary) European search report - dispatched on:EP24.07.2013
ClassificationIPC:A61K9/00, A61K31/535, A61K31/5575, A61K31/542, A61K45/06, A61K31/215
[2013/23]
CPC:
A61K31/216 (EP,US); A61K31/215 (EP,US); A61K31/535 (EP,US);
A61K31/542 (EP,US); A61K31/5575 (EP,US); A61K45/06 (EP,US);
A61K47/44 (US); A61K9/0048 (EP,US); A61P27/02 (EP);
A61P27/06 (EP); A61P27/14 (EP); Y02A50/30 (EP) (-)
C-Set:
A61K31/215, A61K2300/00 (EP,US);
A61K31/535, A61K2300/00 (US,EP);
A61K31/542, A61K2300/00 (US,EP);
A61K31/5575, A61K2300/00 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/17]
Former [2013/23]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Pharmazeutische Zusammensetzung mit erwünschter Bioverfügbarkeit[2013/23]
English:Pharmaceutical composition having desirable bioavailability[2013/23]
French:Composition pharmaceutique à biodisponibilité souhaitable[2013/23]
Examination procedure21.02.2014Amendment by applicant (claims and/or description)
21.02.2014Examination requested  [2014/14]
01.04.2014Despatch of a communication from the examining division (Time limit: M04)
08.08.2014Reply to a communication from the examining division
15.04.2016Despatch of a communication from the examining division (Time limit: M04)
20.05.2016Reply to a communication from the examining division
10.08.2016Despatch of a communication from the examining division (Time limit: M04)
25.08.2016Reply to a communication from the examining division
15.02.2017Cancellation of oral proceeding that was planned for 16.02.2017
16.02.2017Date of oral proceedings (cancelled)
15.03.2017Communication of intention to grant the patent
16.03.2017Fee for grant paid
16.03.2017Fee for publishing/printing paid
16.03.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09722278.0  / EP2265251
Divisional application(s)EP15202422.0  / EP3042646
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20090722278) is  13.09.2011
Opposition(s)Opponent(s)01  26.01.2018  31.01.2018  ADMISSIBLE
Alfred E. Tiefenbacher (GmbH & Co. KG)
Van-der-Smissen-Straße 1
22767 Hamburg / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB, et al, et al
Jungfernstieg 38
20354 Hamburg / DE
 02  26.01.2018  31.01.2018  ADMISSIBLE
Generics [UK] Limited (trading as Mylan)
Building 4
Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Gill Jennings & Every LLP, et al, et al
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
 [2018/10]
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
07.02.2018Invitation to proprietor to file observations on the notice of opposition
14.06.2018Reply of patent proprietor to notice(s) of opposition
19.03.2019Date of oral proceedings
07.05.2019Despatch of minutes of oral proceedings
07.05.2019Date of despatch of rejection of opposition
Appeal following opposition09.07.2019Appeal received No.  T1975/19
17.09.2019Statement of grounds filed
05.07.2019Appeal received No.  T1975/19
17.09.2019Statement of grounds filed
12.06.2024Date of oral proceedings
Fees paidRenewal fee
21.11.2012Renewal fee patent year 03
21.11.2012Renewal fee patent year 04
11.03.2013Renewal fee patent year 05
13.03.2014Renewal fee patent year 06
10.03.2015Renewal fee patent year 07
10.03.2016Renewal fee patent year 08
10.03.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 01/exclusive
For:AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Licencee:Alcon Pharmaceuticals Ltd.
Rue Louis d'Affry 6
Case Postale
1701 Fribourg / CH
Date:18.12.2015
[2016/12]
Lapses during opposition  TooltipHU13.03.2009
AT26.04.2017
CY26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
MK26.04.2017
PL26.04.2017
PT26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
SE14.03.2023
CH31.03.2023
DK31.03.2023
LI31.03.2023
NL01.04.2023
GR09.10.2023
[2024/22]
Former [2024/09]HU13.03.2009
AT26.04.2017
CY26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
MK26.04.2017
PL26.04.2017
PT26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
SE14.03.2023
CH31.03.2023
LI31.03.2023
NL01.04.2023
GR09.10.2023
Former [2024/05]HU13.03.2009
AT26.04.2017
CY26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
MK26.04.2017
PL26.04.2017
PT26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
NL01.04.2023
Former [2020/31]HU13.03.2009
AT26.04.2017
CY26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
MK26.04.2017
PL26.04.2017
PT26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
Former [2020/27]HU13.03.2009
AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
PT26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
Former [2020/15]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
TR26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
Former [2020/08]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
MT13.03.2018
BE31.03.2018
Former [2019/12]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
BE31.03.2018
Former [2019/09]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
IE13.03.2018
LU13.03.2018
Former [2019/04]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
LU13.03.2018
Former [2018/52]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
MC26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
Former [2018/25]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
PL26.04.2017
RO26.04.2017
SI26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
Former [2018/10]AT26.04.2017
CZ26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
PL26.04.2017
RO26.04.2017
SK26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
Former [2018/09]AT26.04.2017
EE26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
PL26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
Former [2017/50]AT26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
LV26.04.2017
PL26.04.2017
BG26.07.2017
NO26.07.2017
IS26.08.2017
Former [2017/49]AT26.04.2017
FI26.04.2017
HR26.04.2017
LT26.04.2017
NO26.07.2017
IS26.08.2017
Documents cited:Search[Y]WO9819680  (ALCON LAB INC [US], et al) [Y] 1-13 * examples 1-8 ** claims 1-6 *;
 [Y]WO9841208  (CIBA GEIGY AG [CH], et al) [Y] 1-13 * examples 1-14 *;
 [Y]WO0003736  (ALCON LAB INC [US]) [Y] 1-13 * page 7, line 11 - line 30 * * examples 1-7 * * claims 1-9 *;
 [Y]US2004082660  (UENO RYUJI [US]) [Y] 1-13 * page 1, paragraph 14 * * table 1 * * claims 1-16 *;
 [Y]US6743439  (CASTILLO ERNESTO J [US], et al) [Y] 1-13 * example 5 *;
 [Y]EP1547599  (SANTEN PHARMACEUTICAL CO LTD [JP]) [Y] 1-13 * page 3, paragraph 22 * * table 2 * * table 3 * * examples *
Examination   - BAUDOUIN CHRISTOPHE ET AL, "In vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE - IOVS, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, (20070901), vol. 48, no. 9, doi:10.1167/IOVS.07-0266, ISSN 0146-0404, pages 4123 - 4128, XP002607568

DOI:   http://dx.doi.org/10.1167/IOVS.07-0266
by applicantUS3931319
 US4027020
 US4407791
 US4522806
 US4525346
 US4836986
 WO9109523
 US5037647
 US5221664
 US5300287
 US5320843
 US5741817
 US5817277
 US6017861
 US6034043
 US6319464
 US6348190
 US2002122831
 US6482799
 US6503497
 JP2003104870
OppositionWO0003736
 US2002009507
    - Department of Health and Human Services, "Travatan® Z", Pharmacology Review - Application number 21-994, (20060302), XP055456902
    - NEAL L. BURSTEIN, "Chapter 1 : Basic Science of Ocular Pharmacology", NEAL L. BURSTEIN, Jimmy D. Bartlett, Clinical Ocular Pharmacology, 2nd edition, Butterworth-Heinemann, (19890517), pages 3 - 10, XP055456908
    - Bernal Et Al, "Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives", Current Eye Research, (19910000), vol. 10, no. 7, pages 645 - 656, XP055265030

DOI:   http://dx.doi.org/10.3109/02713689109013856
    - David A Ammar; Robert Ammar; Malik Noecker; Kahook, "Effects of Benzalkonium Chloride-Preserved, Polyquad-Preserved, and sofZia-Preserved Topical Glaucoma Medications on Human Ocular Eoithelial Cells", Advances in Therapy,, (20101100), vol. 27, no. 11, pages 837 - 845, XP055097387

DOI:   http://dx.doi.org/10.1007/s12325-010-0070-1
    - Richard W. Yee, "The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review", Current Opinion In Ophthalmology, (20070000), vol. 18, pages 134 - 139, XP055456925
    - LABBE et al., "Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS,, (20060800), vol. 22, no. 4, pages 267 - 278, XP055264197

DOI:   http://dx.doi.org/10.1089/jop.2006.22.267
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.